CA2627457C - Botulinum neurotoxin a protein receptor and uses thereof - Google Patents

Botulinum neurotoxin a protein receptor and uses thereof Download PDF

Info

Publication number
CA2627457C
CA2627457C CA2627457A CA2627457A CA2627457C CA 2627457 C CA2627457 C CA 2627457C CA 2627457 A CA2627457 A CA 2627457A CA 2627457 A CA2627457 A CA 2627457A CA 2627457 C CA2627457 C CA 2627457C
Authority
CA
Canada
Prior art keywords
bont
polypeptide
homo sapiens
sv2c
gst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2627457A
Other languages
English (en)
French (fr)
Other versions
CA2627457A1 (en
Inventor
Andreas Rummel
Thomas Binz
Stefan Mahrhold
Hans Bigalke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toxogen GmbH
Original Assignee
Toxogen GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toxogen GmbH filed Critical Toxogen GmbH
Publication of CA2627457A1 publication Critical patent/CA2627457A1/en
Application granted granted Critical
Publication of CA2627457C publication Critical patent/CA2627457C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2627457A 2005-10-28 2006-10-30 Botulinum neurotoxin a protein receptor and uses thereof Active CA2627457C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005051789.7 2005-10-28
DE102005051789.7A DE102005051789B4 (de) 2005-10-28 2005-10-28 Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
PCT/EP2006/010420 WO2007048638A2 (de) 2005-10-28 2006-10-30 Der botulinus neurotoxin a proteinrezeptor und seine anwendungen

Publications (2)

Publication Number Publication Date
CA2627457A1 CA2627457A1 (en) 2007-05-03
CA2627457C true CA2627457C (en) 2014-05-13

Family

ID=37770829

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2627457A Active CA2627457C (en) 2005-10-28 2006-10-30 Botulinum neurotoxin a protein receptor and uses thereof

Country Status (12)

Country Link
US (1) US8476024B2 (https=)
EP (1) EP1940874B1 (https=)
JP (1) JP2009513118A (https=)
KR (1) KR20080068069A (https=)
AT (1) ATE539088T1 (https=)
AU (1) AU2006308122B2 (https=)
CA (1) CA2627457C (https=)
DE (1) DE102005051789B4 (https=)
ES (1) ES2379513T3 (https=)
NZ (1) NZ567312A (https=)
WO (1) WO2007048638A2 (https=)
ZA (1) ZA200803403B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
US7985554B2 (en) 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof
WO2009008916A2 (en) 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US9000131B2 (en) * 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
US8771707B2 (en) * 2008-09-30 2014-07-08 Wisconsin Alumni Research Foundation Botulinum neurotoxin E receptors and uses thereof
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
UA116985C2 (uk) 2012-05-30 2018-06-11 Президент Енд Феллоуз Оф Гарвард Колледж Рекомбінантний ботулінічний нейротоксин
WO2014079495A1 (en) * 2012-11-21 2014-05-30 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
PT3274364T (pt) 2015-03-26 2021-11-05 Harvard College Neurotoxina botulínica manipulada
KR101670188B1 (ko) 2015-11-09 2016-10-27 충북대학교 산학협력단 보툴리눔 신경독소 ｅ형에 특이적인 폴리펩타이드 및 이의 용도
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
KR101958312B1 (ko) * 2017-09-06 2019-07-02 국방과학연구소 보툴리눔 a형 독소에 대한 항체
IL272002A (en) 2020-01-13 2021-07-29 The Israel Institute Of Biological Res Iibr Methods for identifying anti clostridial neurotoxin compounds
WO2023210585A1 (ja) * 2022-04-25 2023-11-02 株式会社Jiksak Bioengineering 標的化剤
WO2025089343A1 (ja) * 2023-10-25 2025-05-01 株式会社Jiksak Bioengineering 抗シナプス小胞糖タンパク質２ｃ抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016233A2 (en) 2002-10-31 2005-02-24 Wisconsin Alumni Research Foundation Botulinum neurotoxin b receptors and use thereof
CA2484115C (en) * 2002-12-03 2007-01-30 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
US7985554B2 (en) * 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof

Also Published As

Publication number Publication date
US8476024B2 (en) 2013-07-02
AU2006308122B2 (en) 2011-06-30
NZ567312A (en) 2011-09-30
EP1940874A2 (de) 2008-07-09
EP1940874B1 (de) 2011-12-28
DE102005051789B4 (de) 2014-08-07
DE102005051789A1 (de) 2007-05-10
WO2007048638A2 (de) 2007-05-03
KR20080068069A (ko) 2008-07-22
US20090252722A1 (en) 2009-10-08
ZA200803403B (en) 2009-02-25
JP2009513118A (ja) 2009-04-02
WO2007048638A3 (de) 2007-07-26
CA2627457A1 (en) 2007-05-03
ES2379513T3 (es) 2012-04-26
AU2006308122A1 (en) 2007-05-03
ATE539088T1 (de) 2012-01-15

Similar Documents

Publication Publication Date Title
CA2627457C (en) Botulinum neurotoxin a protein receptor and uses thereof
Rummel Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity
DE60032367T2 (de) Aktivierbare rekombinante neurotoxine
Gaisano et al. Tetanus toxin light chain cleaves a vesicle-associated membrane protein (VAMP) isoform 2 in rat pancreatic zymogen granules and inhibits enzyme secretion.
AU2007347781B2 (en) Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
Dong et al. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells
Wang et al. Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics
JP5134540B2 (ja) クロストリジウム毒素活性化クロストリジウム毒素
AU2010267963B2 (en) Neurotoxins exhibiting shortened biological activity
Chaddock et al. Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A
US20220033447A1 (en) Engineered botulinum neurotoxin
US20040220386A1 (en) Clostridial neurotoxin compositions and modified clostridial neurotoxins
JP2008538902A (ja) 神経細胞をターゲッティングするための担体
Wang et al. Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis
Baldwin et al. Association of botulinum neurotoxin serotypes a and B with synaptic vesicle protein complexes
KR20200127175A (ko) 보툴리눔 신경독소 바이오하이브리드
Li et al. Recombinant forms of tetanus toxin engineered for examining and exploiting neuronal trafficking pathways
Apland et al. Inhibition of neurotransmitter release by peptides that mimic the N-terminal domain of SNAP-25
RU2816855C2 (ru) Биогибрид ботулинического нейротоксина
Rummel The Dual-Receptor Recognition of Botulinum Neurotoxins: Polysialo-Gangliosides and Synaptic Vesicle Proteins Mediate the Neuronal Entry of Botulinum Neurotoxins by Binding to its C-terminal 50-kDa HC fragment
WO2021190987A1 (en) Engineered botulinum neurotoxin serotype e
Larsen The role of calcium ion-dependent interactions between synaptotagmin and SNARE complexes in regulated exocytosis
Yan Structure-activity Relationship of CbnB2 and LeuA, and the Search for the Putative Receptor of LeuA.

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250430